インスリン注入ポンプの世界市場 - 2023年～2030年

概要

インスリン注入ポンプは小型でコンピュータ化された装置です。インスリンポンプは糖尿病患者の血糖管理を便利にすることができます。これらの小さなデバイスは、特定の時間にインスリンの用量を提供します。多くの人々は、インスリンポンプは、インスリンペン注射のような他のデバイスよりも柔軟なオプションであることがわかります。インスリンポンプは永久的なものである必要はなく、いつでも別のインスリン管理方法に切り替えることができます。

インスリンポンプは、ライフスタイルの自由と柔軟性を提供することで知られています。1型糖尿病のすべての人々と2型糖尿病の一部の人々は、彼らの残りの人生のためにインスリン注射のオプションのいくつかのタイプを必要とする、これらのインスリンポンプは、糖尿病の治療をより容易にすることができます。投与は、カテーテルとして知られる柔軟なプラスチックチューブを通して行われます。小さな針の助けを借りて、カテーテルは皮膚から脂肪組織に挿入され、テープで固定されます。チューブと針の組み合わせは輸液セットと呼ばれます。

市場力学：促進要因

高度インスリン注入ポンプの採用増加

高度なインスリン注入ポンプの採用が増加していることが、予測期間にわたって市場を牽引するとみられます。インスリン注入ポンプの進歩は、糖尿病のより良い治療に役立ち、その結果、患者の転帰が改善されます。例えば、2022年03月08日、Medtronic plcの完全子会社であるIndia Medtronic Private Limitedは、インドでMiniMed 780Gシステムを発売しました。

MiniMed 780Gシステムは、7歳～80歳の1型糖尿病治療用の次世代クローズドループインスリンポンプシステムです。同社の最先端のスマートガード技術を活用したこのシステムは、基礎インスリンと補正用ボーラスの両方を5分ごとに自動投与し、糖尿病患者がより簡単に高低差を回避できるよう支援します。

さらに、インスリン注入ポンプは、他のデバイスよりも大きな利点があり、これらのポンプの進歩は、インスリン注入を制御し、管理するのに役立ちます。先進的な輸液ポンプは、より正確で持続的なインスリン投与を可能にし、血糖コントロールを大幅に改善することができます。これは、糖尿病患者の長期的な健康状態の改善と合併症の減少につながります。

例えば、2023年2月14日、EOFlow Co.は、チューブレス、ウェアラブル、使い捨てのインスリンポンプ「EOPatch」をUAEで発売しました。UAEでは、真新しいNarshaアプリを使用して、AndroidおよびiOSスマートフォンから直接EOPatchでインスリン注入を制御・管理することが可能になります。

さらに、規制当局の承認は、新しい先進的な機器の開発に対する患者の信頼を高める。例えば、2022年2月16日、インスリンデリバリーと糖尿病テクノロジーのリーディングカンパニーであるTandem Diabetes Care, Inc.は、t：connectモバイルアプリを使用したt：slim X2インスリンポンプでのボーラスインスリン投与の米国食品医薬品局（FDA）認可を発表しました。これは、iOSとAndroidの両OSでインスリン投与を開始できるスマートフォンアプリとして、史上初めてFDAの認可を受けたことになります。

さらに、糖尿病有病率の増加、FDA承認の増加、臨床試験の増加、認知度の向上、新規デバイスの開発における技術進歩は、予測期間にわたって市場を牽引すると予想される要因です。

阻害要因

機器に関連する合併症、インスリン注入ポンプの高コスト、機器に関連する技術的問題、代替治療オプションの存在などの要因が市場の阻害要因になると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 先進インスリン注入ポンプの採用増加
  • 抑制要因
    • デバイスに関連する合併症
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• パイプライン分析
• アンメットニーズ
• 特許分析
• DMIオピニオン

第6章 COVID-19分析

第7章 コンポーネント別

• インスリンポンプ
• 輸液セット
• リザーバー

第8章 用途別

• I型糖尿病
• II型糖尿病

第9章 エンドユーザー別

• 病院
• 専門クリニック
• 在宅医療
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他のアジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Medtronic plc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Insulet Corporation
• Tandem Diabetes Care, Inc.
• Ascensia Diabetes Care Holdings AG
• Ypsomed AG
• F. Hoffmann-La Roche Ltd.
• Shinmyung Mediyes CO., LTD.
• Abbott Laboratories
• SOOIL Developments Co., Ltd
• Smiths Group plc

第13章 付録

Overview

Insulin infusion pumps are small and computerized devices. Insulin pumps can help diabetes patients conveniently manage their blood sugar. These small devices deliver doses of insulin at specific times. Many people find that insulin pumps are a more flexible option than other devices like insulin pen injections. Insulin pumps don't have to be permanent and can switch to another insulin management method at any time.

Insulin pumps are known to offer lifestyle freedom and flexibility. All people with Type 1 diabetes and some people with Type 2 diabetes will need some type of insulin injection option for the rest of their lives, these insulin pumps can make diabetes treatment more easier. Doses are delivered through a flexible plastic tube known as a catheter. With the aid of a small needle, the catheter is inserted through the skin into the fatty tissue and is taped in place. The tube/needle combination is called an infusion set.

Market Dynamics: Drivers

Increasing adoption of advanced insulin infusion pumps

The increasing adoption of advanced insulin infusion pumps is expected to drive the market over the forecast period. The advancements in insulin infusion pumps helps in the better treatment of diabetes, resulting in better patient outcomes. For instance, on March 08, 2022, India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc launched the MiniMed 780G system in India.

The MiniMed 780G system is a next-generation closed-loop insulin pump system for the treatment of type 1 diabetes in people aged 7 to 80 years. Leveraging the company's most advanced SmartGuard technology, the system automates the delivery of both basal insulin and correction boluses every five minutes to help people with diabetes avoid highs and lows with greater ease.

Moreover, insulin infusion pumps have greater advantages than other devices, the advancements in these pumps helps to control and manage the insulin infusions. Advanced infusion pumps offer more precise and continuous insulin delivery, which can significantly improve blood glucose control. This can lead to better long-term health outcomes and reduced complications for individuals with diabetes.

For instance, on february 14, 2023, EOFlow Co. launched its tubeless, wearable, and disposable insulin pump "EOPatch" in the UAE. It becomes possible in the UAE to control and manage insulin infusions with EOPatch directly from Android and iOS smartphones using the brand-new Narsha app.

In addition, the regulatory approvals increase the trust in patients about the development of novel advanced devices. For instance, on February 16, 2022, Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, released the U.S. Food and Drug Administration (FDA) clearance of bolus insulin dosing on the t:slim X2 insulin pump using the t:connect mobile app. This represents the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems.

Further, the increasing prevalence of diabetes, rising FDA approvals, increasing clinical trials, increasing awareness and technological advancements in the development of novel devices are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the devices, the high cost of the insulin infusion pumps, technical issues associated with the devices and presence of alternative treatment options are expected to hamper the market.

Segment Analysis

The global insulin infusion pumps market is segmented based on component, application, end-user and region.

The insulin pumps segment accounted for approximately 45.3% of the insulin infusion pumps market share

The insulin pumps segment is expected to hold the largest market share over the forecast period. The increasing prevalence of diabetes is expected to increase the demand for the insulin pumps. For instance, according to the Centers for Disease Control and Prevention, 2022, 37.3 million people have diabetes.

Ongoing advancements in insulin pump technology, such as integration with continuous glucose monitoring (CGM) systems and improved user interfaces, may attract more users. Insulin pumps offer flexibility in insulin dosing, allowing users to customize their treatment plans. Their convenience, including reduced injection frequency, can make them an attractive option.

For instance, on April 25, 2023, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod brand of products, released the FDA clearance of its latest innovation, Omnipod GO, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and technological advancements. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in clinical trials, leads to the launch of novel and advanced devices in the region.

For instance, on November 15, 2022, Medtronic launched a new infusion set with a wear time of up to seven days for insulin pumps in the US. Developed in collaboration with Convatec Infusion Care, the new Medtronic Extended Infusion Set is claimed to be the first and only infusion set that is designed for double the wear time. The new infusion set leverages advanced materials to help minimize insulin preservative loss, maintain insulin flow and stability, and double the infusion set wear time.

Furthermore, the region is also known for its innovation and investment in research and development in the insulin infusion pumps. Technological advancements in North America especially in United States can lead to the introduction of cutting-edge products and solutions that attract a more users.

In addition, on July 07, 2020, Medtronic plc, the global leader in medical technology, introduced the MiniMed Mio Advance infusion set to all Medtronic insulin pump customers in the United States. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed portfolio of infusion sets and gives people using insulin pumps an optimal user experience with fewer steps.

Competitive Landscape

The major global players in the insulin infusion pumps market include: Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, Ypsomed AG, F. Hoffmann-La Roche Ltd., Shinmyung Mediyes CO., LTD., Abbott Laboratories, SOOIL Developments Co., Ltd and Smiths Group plc, among others.

Key Developments

• On June 21, 2023, Insulet commercially launched its Omnipod 5 automated insulin delivery system in the United Kingdom. Acton, Massachusetts-based Insulet launched Omnipod 5 insulin pumps for individuals aged two years and older with type 1 diabetes.
• On April 21, 2023, Medtronic plc, the global leader in medical technology, cleared the U.S. Food and Drug Administration (FDA) approval of its MiniMed 780G system with the Guardian 4 sensor requiring no fingersticks while in SmartGuard technology. This milestone marks the approval of the only system with meal detection technology that provides automatic adjustments and corrections to sugar levels every 5 minutes.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global insulin infusion pumps market. Many people with diabetes reduced their visits during the pandemic to minimize the risk of exposure to the virus. As a result, there was a decline in new pump prescriptions and fittings, impacting market growth. Healthcare providers increasingly turned to telehealth and remote monitoring solutions to provide care to individuals with diabetes. The pandemic also disrupted the supply chain of these devices globally.

Why Purchase the Report?

• To visualize the global insulin infusion pumps market segmentation based on component, application end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of insulin infusion pumps market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global insulin infusion pumps market report would provide approximately 61 tables, 57 figures, and 188 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Component
• 3.2. Snippet by Application
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Adoption of Advanced Insulin Infusion Pumps
  • 4.1.2. Restraints
    • 4.1.2.1. Complications Associated with the Devices
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Pipeline Analysis
• 5.6. Unmet Needs
• 5.7. Patent Analysis
• 5.8. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Component

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 7.1.2. Market Attractiveness Index, By Component
• 7.2. Insulin Pumps*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Infusion Sets
• 7.4. Reservoirs

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Type I Diabetes*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Type II Diabetes

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Specialty Clinics
• 9.4. Home Care Settings
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Medtronic plc*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Insulet Corporation
• 12.3. Tandem Diabetes Care, Inc.
• 12.4. Ascensia Diabetes Care Holdings AG
• 12.5. Ypsomed AG
• 12.6. F. Hoffmann-La Roche Ltd.
• 12.7. Shinmyung Mediyes CO., LTD.
• 12.8. Abbott Laboratories
• 12.9. SOOIL Developments Co., Ltd
• 12.10. Smiths Group plc

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us